Reliance Global Group (EZRA) Q1 2026 earnings summary

Executive summary

• Advanced Scale51 strategy with targeted investments in technology and life sciences, including increased ownership in Enquantum and the launch of LifeSci Global Group, while maintaining insurance and InsurTech operations as a stable foundation.

• Focused on simplifying operations, strengthening the balance sheet, and establishing a framework for long-term growth, now entering a more active execution phase.

• Strategic Ventures segment launched in 2026, focusing on technology and life sciences investments, reporting a $0.4M net loss in its first quarter.

• Enhanced RELI Exchange platform and expanded direct-to-consumer reach with 5MinuteInsure.com, supporting organic growth and operational efficiency.

• Major developments include the formation of LifeSci Global Group, a $2M investment in Innervate Radiopharmaceuticals, and a 1-for-40 reverse stock split to regain Nasdaq compliance.

Financial highlights

• Unrestricted cash increased to $2.3M from $1.3M sequentially; combined cash (including restricted) rose to $3.24M from $2.7M.

• Working capital improved to $2.6M from $1.9M; stockholders' equity increased to $7.4M from $6.4M.

• Commission income was $3.8M, down from $4.2M year-over-year due to divestitures, but retained businesses saw 11% organic revenue growth.

• Net loss improved to $1.4M from $1.7M year-over-year, driven by lower operating and interest expenses.

• Adjusted EBITDA was -$0.4M versus +$0.1M prior year, reflecting lower stock-based compensation add-backs.

Outlook and guidance

• Plans to continue disciplined execution of the dual-segment model, broadening investment opportunities and advancing current holdings.

• Expects further organic growth in insurance segment, leveraging technology and AI to enhance agent productivity and carrier relationships.

• Prioritizing growth in cybersecurity, data-driven technologies, and life sciences through milestone-based investments.

• Management believes current liquidity and capital resources are sufficient for at least the next twelve months.

• Life sciences investments will focus on companies with proven performance and strong management teams, not early-stage ventures.